Inotiv, Inc. ( (NOTV) ) has released its Q3 earnings. Here is a breakdown of the information Inotiv, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Inotiv, Inc. is a prominent contract research organization that provides nonclinical and analytical drug discovery and development services, as well as research models and related products, primarily serving the pharmaceutical and biotechnology industries. The company is recognized for its commitment to enhancing drug and medical device development efficiency while reducing costs.
Inotiv, Inc. has reported a significant increase in revenue for the third quarter of fiscal 2025, with a 23.5% rise to $130.7 million compared to the same period last year. The company’s year-to-date revenue also saw a modest increase of 4.0%, reaching $374.9 million. These results reflect the company’s ongoing efforts to meet its financial goals and improve its operational performance.
Key financial highlights from the third quarter include a notable 34.1% increase in Research Models and Services (RMS) revenue and an 8.9% rise in Discovery and Safety Assessment (DSA) revenue. The company’s adjusted EBITDA improved significantly to $11.6 million, up from $0.1 million in the previous year. Despite a consolidated net loss of $17.6 million, this represents an improvement from the $26.1 million loss recorded in the same quarter of the previous year.
The company has made strategic progress in its operations, with a focus on client satisfaction and the delivery of high-quality services. Recent developments include the conclusion of an SEC investigation without enforcement action and ongoing efforts to optimize its U.S. operations. The company is also addressing legal challenges with a $10 million accrual for ongoing lawsuits, which it expects to recover through insurance.
Looking ahead, Inotiv remains committed to executing its strategic plans and enhancing its service offerings. The company aims to continue building a strong client base and improving its financial performance, supported by its recent operational improvements and strategic initiatives.